Neoantigen-based Therapeutic Cancer Vaccine GRT-C903

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.

**Synonyms:** - GRT C903 - GRT-C903 - GRTC903 - Priming Cancer Vaccine GRT-C903 - Priming Vaccine GRT-C903 - Shared Neoantigen Cancer Vaccine Prime GRT-C903 - Shared Neoantigen Priming Cancer Vaccine GRT-C903